Stereotactic body radiation therapy for recurrent head & neck cancers: Rethinking nonoperative salvage strategies

Future Oncology

Volumn 5, Issue 9, 2009, Pages 1321-1325

  Heron, Dwight E ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; PACLITAXEL;

ADVANCED CANCER; BONE NECROSIS; BRACHYTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOW DRUG DOSE; MUCOSA INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RECURRENT CANCER; RETREATMENT; SALVAGE THERAPY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SURVIVAL TIME; TISSUE NECROSIS; XEROSTOMIA; HEAD AND NECK TUMOR; RADIOSURGERY; TUMOR RECURRENCE;

HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIOSURGERY; SALVAGE THERAPY;

EID: 74949106601     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.107     Document Type: Editorial

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Stell PM: Survival times in end-stage head and neck cancer. Eur. J. Surg. Oncol. 15, 407-410 (1989).
3. Forastiere AA, Metch B, Schuller DE et al.: Randomised comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamouscell carcinoma of the head and neck. A Southwest Oncology Group study. J. Clin. Oncol. 10, 1245-1251 (1992).
4. Vokes EE, Mick R, Kies MS et al.: Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J. Clin. Oncol. 14, 1663-1671 (1996).
5. Clavel M, Vermorken JB, Cognetti F et al.: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol. 5, 521-526 (1994).
6. Jacobs C, Lyman G, Velez-Garcia E et al.: A Phase II randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 10, 257-263 (1992).
7. Karamouzis MV, Friedland D, Johnson R, Rajasenan K, Branstetter B, Argiris A: Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis. J. Clin. Oncol. 25(185), 6049 (2007).
8. Pomp J, Levendag PC, Van Putten WL: Reirradiation of recurrent tumors in the head and neck. Am. J. Clin. Oncol. 11, 543-549 (1988).
9. Emami B, Perez CA: Combination of surgery, irradiation, and hyperthermia in treatment of recurrences of malignant tumors. Int. J. Radiat. Oncol. Biol. Phys. 13, 611-613 (1987).
10. Langlios D, Eschwege F, Kramar A, Richard JM: Re-irradiation of recurrent tumors in the head and neck. Radiother. Oncol. 3, 27-33 (1985).
11. Salama JK, Vokes EE, Chmura SJ et al.: Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 64, 382-391 (2006).
12. Stevens KR Jr, Britsch A, Moss WT: High-dose re-irradiation of head and neck cancer with curative intent. Int. J. Radiat. Oncol. Biol. Phys. 29, 687-698 (1994).
13. Langer CJ, Harris J, Horwitz EM et al.: Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J. Clin. Oncol. 25, 4800-4805 (2007).
14. Lu TX, Mai WY, Teh BS et al.: Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 58, 682-687 (2004).
15. Voynov G, Heron DE, Burton S et al.: Frameless stereotactic radiosurgery for recurrent head and neck carcinoma. Technol. Cancer. Res. Treat. 5, 529-535 (2006).
16. Heron DE, Ferris RL, Karamouzis M et al.: Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a Phase I dose-escalation trial. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrob.2008.12.075 (2009) (Epub ahead of print).
17. Siddiqui F, Patel M, Khan M et al.: Stereotactic body radiation therapy for primary, recurrent, and metastatic tumor in the head-and-neck region. Int. J. Radiat. Oncol. Biol. Phys. 74, 1047-1053 (2009).
18. Rwigema JC, Heron DE, Ferris RL et al.: Fractionated stereotactic body radiation therapy in the treatment of previously irradiated recurrent head and neck carcinoma - updated report of the University of Pittsburgh Cancer Experience. Am. J. Clin. Oncol. (2009) (Epub ahead of print).
19. Bonner JA, Harari PM, Giralt J et al.: Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).